Publication Name	World Journal of Gastroenterology
Manuscript ID	6330
Country	Croatia

Received	2013-10-13 23:22
Peer-Review Started	2013-10-16 08:32
To Make the First Decision	2013-12-04 09:05
Return for Revision	2013-12-04 21:37
Revised	2013-12-07 21:38
Second Decision	2014-01-08 18:14
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2014-01-08 18:37
Articles in Press	2014-05-23 11:33
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2014-05-28 11:46
Publish the Manuscript Online	2014-06-21 13:56

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Topic Highlights
Article Title	Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease
Manuscript Source	Invited Manuscript
All Author List	Kristina Blaslov, Tomislav Bulum, Karin Zibar and Lea Duvnjak
Funding Agency and Grant Number
Corresponding Author	Kristina Blaslov, MD, Vuk Vrhovac Clinic for Diabetes, Endocrinology and Metabolic Diseases, University Hospital Merkur, School of Medicine, University of Zagreb, Dugi dol 4a, 10000 Zagreb, Croatia. kblaslov@gmail.com
Key Words	Non-alcoholic fatty liver disease; Insulin resistance; Glucagon-like peptide-1; Dipeptidyl peptidase-4; Metabolic syndrome
Core Tip	Insulin resistance is considered a fundamental problem in the genesis of hepatic steatosis and the pathophysiology of its development. In this review we discussed the role of incretin based therapies, including glucagon like peptide-1 (GLP-1) analogues and dipeptidyl peptidase-4 (DPP-4) inhibitors as a potential novel agents in non-alcoholic fatty liver disease treatment comprising experimental and clinical data available so far which generally suggest that GLP-1 analogues as well as DPP-4 inhibitors might be involved in direct pathways of liver fat elimination. To the best of our knowledge, this is the first review comprising all the data about incretin based therapies in fatty liver treatment.
Publish Date	2014-06-21 13:56
Citation	Blaslov K, Bulum T, Zibar K, Duvnjak L. Incretin based therapies: A novel treatment approach for non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(23): 7356-7365
URL	http://www.wjgnet.com/1007-9327/full/v20/i23/7356.htm
DOI	http://dx.doi.org/10.3748/wjg.v20.i23.7356

Full Article (PDF)	WJG-20-7356.pdf
Full Article (Word)	WJG-20-7356.doc
Manuscript File	6330-Review.doc
Answering Reviewers	6330-Answering reviewers.pdf
Copyright License Agreement	6330-Copyright assignment.doc
Peer-review Report	6330-Peer review(s).pdf
Scientific Editor Work List	6330-Scientific editor work list.doc